Disease-modifying drugs and Parkinson's disease

Progress in Neurobiology

Volumn 84, Issue 1, 2008, Pages 25-39

  Allain, Hervé ^a   Bentué Ferrer, Danièle ^a   Akwa, Yvette ^b  

^a Faculté de Médecine   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Animal models; Clinical trials; Drugs; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; ALPHA SYNUCLEIN; CALCIUM CHANNEL L TYPE; CREATINE; DOPAMINE RECEPTOR STIMULATING AGENT; GANGLIOSIDE GM1; GLUTAMIC ACID; GPI 1485; LEVODOPA; LISURIDE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROIMMUNOPHILIN; OXIDOPAMINE; PARAQUAT; PESTICIDE; PETHIDINE; PLACEBO; PRAMIPEXOLE; PROTEASOME INHIBITOR; RASAGILINE; RESERPINE; RILUZOLE; ROPINIROLE; ROTENONE; SELEGILINE; TOCOPHEROL; UBIQUINONE; UNINDEXED DRUG;

APOPTOSIS; CELL MIGRATION; CELL PROTECTION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; ENDOPLASMIC RETICULUM; EXCITOTOXICITY; GENETIC DATABASE; GENETIC MODEL; GOLGI COMPLEX; HUMAN; INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; VALIDATION STUDY;

ANIMALS; ANTIPARKINSON AGENTS; APOPTOSIS; BRAIN; CYTOPROTECTION; DISEASE MODELS, ANIMAL; HUMANS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 37149050857     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2007.10.003     Document Type: Review

References (238)

1. Abou-Sleiman P.M., Healy D.G., and Wood N.W. Uses of Parkinson's disease: genetics of DJ-1. Cell. Tissue Res. 318 (2004) 185-188
2. Akwa Y., Allain H., Bentue-Ferrer D., Berr C., Bordet R., Geerts H., Nieoullon A., Onteniente B., and Vercelletto M. Neuroprotection and neurodegenerative disorders: from biology to therapeutics. Alzheimer Dis. Assoc. Disord. 19 (2005) 226-239
3. Alexi T., Borlongan C.V., Faull R.L., Williams C.E., Clark R.G., Gluckman P.D., and Hughes P.E. Neuroprotective strategies for basal ganglion degeneration: Parkinson's and Huntington's Diseases. Prog. Neurobiol. 60 (2000) 409-470
4. Allain H., Destee A., Petit H., Patay M., Schuck S., Bentue-Ferrer D., and Le Cavorzin P. Five-year follow-up early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. Eur. Neurol. 44 (2000) 22-30
5. Asanuma M., Miyazaki I., and Ogawa N. Dopamine-or l-Dopa-induced neurotoxicity: the role of dopamine quinine formation and thyrosinase in a model of Parkinson's disease. Neurotox. Res. 5 (2003) 165-176
6. Bähr M. Neuroprotection: Models, Mechanisms and Therapies (2004), Wiley-VCH Verlag Gmbh, Weinheim (Germany) p. 369
7. Bales K.R. Neurodegenerative disease research in the 21st century. Drug Discov. Today 9 (2004) 553-556
8. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
9. Baudry M., Bi X., and Schreiber S.S. Synaptic Plasticity; Basic Mechanisms to Clinical Applications (2005), Taylor & Francis Group Editor, Florida (USA) p. 508
10. Bayer T.A., Jäkälä P., Hartmann T., Havas L., McLean C., Culvenor J.G., Li Q.X., Masters C.L., Falkai P., and Beyreuther K. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Neurosci. Lett. 266 (1999) 213-216
11. Beal M.F. Excitotoxicity and nitric oxid in Parkinson's disease pathogenesis. Ann Neurol. 51 (2002) S110-S114
12. 123I-FP-CIT SPECT striatal uptake. Mov. Disord. 15 (2000) 692-698
13. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/Riluzole Study Group. N. Eng. J. Med. 330 (1994) 585-591
14. Bentue-Ferrer D., Menard G., and Allain H. Monoamine oxidase B inhibitors. Current status and future potential. CNS Drugs 6 (1996) 217-236
15. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
16. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
17. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., Na H.M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R., and Greenamyre J.T. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22 (2006) 404-420
18. Bezard E. Neuroprotection for Parkinson's disease: a call for clinically driven experimental design. Lancet Neurol. 2 (2003) 393
19. Bodles A.M., Guthrie D.J., Greer B., and Irvine G.B. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid deposition responsible for its aggregation and toxicity. J. Neurochem. 78 (2001) 384-395
20. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
21. Bonini N.M., and Giasson B.I. Sanaring the function of alpha-synuclein. Cell 123 (2005) 359-361
22. Bossy-Wetzel E., Schwarzenbacker R., and Lipton S.A. Molecular pathways to neurodegeneration. Nat. Med. 10 Suppl. (2004) S2-S9
23. Bowenkamp K.E., Lapchak P.A., Hoffer B.J., Miller P.J., and Bickford P.C. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Exp. Neurol. 145 (1997) 104-117
24. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 84-94
25. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., and Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823 (1999) 1-10
26. Brooks D.J. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S110-S119
27. Caldwell M., Reymann J.M., Allain H., Leonard B.E., and Bentue-Ferrer D. Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats. Brain Res. 771 (1997) 305-318
28. Calne D.B., and Langston J.W. Aetiology of Parkinson's disease. Lancet 2 (1983) 1457-1459
29. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., and Surmeier D.J. Rejuvenation protects neurons in mouse models of Parkinson's disease. Nature 447 (2007) 1081-1086
30. Chaudhuri K.R., Healy D.G., Schapira A.H., and National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5 (2006) 235-245
31. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk of Parkinson's disease. Ann. Neurol. 58 (2005) 963-967
32. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L., and Dawson T.M. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson's disease. Nat. Med. 7 (2001) 1144-1150
33. Clarke C.E. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol. 3 (2004) 466-474
34. Clarke C.E. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?. Mov. Disord. 19 (2004) 491-498
35. Cole N.B., and Murphy D.D. The cell biology of alpha-synuclein: a sticky problem?. Neuromol. Med. 1 (2002) 95-109
36. Colin E., Regulier E., Perrin V., Durr A., Brice A., Aebischer P., Deglon N., Humbert S., and Saudou F. Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci. 21 (2005) 1475-1488
37. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Harper J.D., Williamson R.E., and Lansbury Jr. P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 571-576
38. Conway K.A., Rochet J.C., Bieganski R.M., and Landsbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
39. Cooper A.A., Gitler A.D., Cashikar A., Haynes C.M., Hill K.J., Bhullar B., Liu K., Xu K., Strathearn K.E., Liu F., Cao S., Caldwell K.A., Caldwell G.A., Marsischky G., Kolodner R.D., Labaer J., Rochet J.C., Bonini N.M., and Lindquist S. α-Synuclein blocks ER-golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 (2006) 324-328
40. Culvenor J.G., mcLean C.A., Cutt S., Campbell B.C., Maher F., Jäkälä P., Hartmann T., Beyreuther K., Masters C.L., and Li Q.X. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited NAC and alpha-synuclein are not associated with Abeta amyloid. Am. J. Pathol. 155 (1999) 1173-1181
41. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., and Hen R. Resistance of alpha-synuclein null mice to parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 14524-14529
42. Deng H., Le W., Guo Y., Hunter C.B., Xie W., and Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann. Neurol. 57 (2005) 933-934
43. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., and Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 54 (2000) S21-S23
44. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 (2002) 303-317
45. Dichter M.A., and Locke R.E. Clinical trials in Neuroprotection. Exp. Opin. Emerg. Drugs 8 (2003) 267-271
46. Double K.L., Ben-Shachar D., Youdim M.B., Zecca L., Riederer P., and Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol. 24 (2002) 621-628
47. Ebadi M., Govitrapong P., Sharma S., Muralikrishnan D., Shavali S., Pellett L., Schafer R., Albano C., and Eken J. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals. Recept. 10 (2001) 224-253
48. Eberhardt O., and Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol. Lett. 139 (2003) 135-151
49. Eidelberg D., Moeller J.R., Ishikawa T., Dhawan V., Spetsieris P., Chaly T., Robeson W., Dahl J.R., and Margouleff D. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J. Nucl. Med. 36 (1995) 378-383
50. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 991 (2003) 1-14
51. Fahn S., and Sulzer D. Neurodegeneration and neuroprotection in Parkinson's disease. NeuroRx 1 (2004) 139-154
52. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease. J. Neurol. 252 Suppl. 4 (2005) IV/37-IV/42
53. Faucheux B.A., Martin M.E., Beaumont C., Hauw J.J., Agid Y., and Hirsch E.C. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 85 (2003) 1142-1148
54. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
55. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
56. Findley L., Aujla M., Bain P.G., Baker M., Beech C., Bowman C., Holmes J., Kingdom W.K., MacMahon D.G., Peto V., and Playfer J.R. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov. Disord. 18 (2003) 1139-1145
57. Fleming S.M., Fernagut P.O., and Chesselet M.F. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2 (2005) 495-503
58. Fogal B., Trettel J., Uliasz T.F., Levine E.S., and Hewett S.J. Changes in secondary glutamate release underlie the developmental regulation of excitotoxic neuronal cell death. Neuroscience 132 (2005) 929-942
59. Forno L.S. The Lewy body in Parkinson's disease. Adv. Neurol. 45 (1987) 35-43
60. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
61. 18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease. Synapse 51 (2004) 119-127
62. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348 (2003) 1365-1375
63. Gash D.M., Zhang Z., Ai Y., Grondin R., Coffey R., and Gerhardt G.A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann. Neurol. 58 (2005) 224-233
64. Gasser T. Genetics of Parkinson's disease. J. Neurol. 248 (2001) 833-840
65. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., Latchman D.S., Holton J.L., Wood N.W., and Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006) 1720-1731
66. Giaime E., Sunyach C., Herrant M., Grosso S., Auberger P., McLean P.J., Checler F., and da Costa C.A. Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway. J. Biol. Chem. 281 (2006) 11515-11522
67. Giasson B.I., and Lee V.M. Parkin and the molecular pathways of Parkinson's disease. Neuron 31 (2001) 885-888
68. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., Trojanowski J.Q., and Lee V.M. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 (2003) 636-640
69. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
70. Green A.R., Odergren T., and Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents. Trends Pharmacol. Sci. 24 (2003) 402-408
71. Goldwurm S., Di Fonzo A., Simons E.J., Rohe C.F., Zini M., Canesi M., Tesei S., Zecchinelli A., Antonini A., Mariani C., Meucci N., Sacilotto G., Sironi F., Salani G., Ferreira J., Chien H.F., Fabrizio E., Vanacore N., Dalla Libera A., Stocchi F., Diroma C., Lamberti P., Sampaio C., Meco G., Barbosa E., Bertoli-Avella A.M., Breedveld G.J., Oostra B.A., Pezzoli G., and Bonifati V. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J. Med. Genet. 42 (2005) e65
72. Hancock D.B., Martin E.R., Stajich J.M., Jewett R., Stacy M.A., Scott B.L., Vance J.M., and Scott W.K. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch. Neurol. 64 (2007) 576-580
73. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., and Hirsch E.C. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 2875-2880
74. Hashimoto M., Bar-On P., Ho G., Takenouchi T., Rockenstein E., Crews L., and Masliah E. Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J. Biol. Chem. 279 (2004) 23622-23629
75. Heemskerk J., Tobin A.J., and Gravina B. From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat. Neurosci. 5 Suppl. (2002) 1027-1029
76. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., Rudolf J., Herholz K., and Heiss W.D. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal Fluorodopa F18 activity. Arch. Neurol. 62 (2005) 378-382
77. Hinoi E., Takarada T., Tsuchihashi Y., and Yoneda Y. Glutamate transporters as drug targets. CNS Neurol. Disord. 4 (2005) 211-220
78. Horowski R., Horowski L., Calne S.M., and Calne D.B. From Wilhem von Humbolt to Hitler-are prominent people more prone to have Parkinson's disease?. Parkinsonism Relat. Disord. 6 (2000) 205-214
79. Hughes A.J., Daniel S.E., and Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 (2001) 1497-1499
80. Hughes T.A., Ross H.F., Musa S., Bhattacherjee S., Nathan R.N., Mindham R.H., and Spokes E.G. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54 (2000) 1596-1602
81. Hurtig H.I. Problems with current pharmacologic treatment of Parkinson's disease. Exp. Neurol. 144 (1997) 10-16
82. Huse D.M., Schulman K., Orsini L., Castelli-Haley J., Kennedy S., and Lenhart G. Burden of illness in Parkinson's disease. Mov. Disord. 20 (2005) 1449-1454
83. Imai Y., and Takahashi R. How do Parkin mutations result in neurodegeneration?. Curr. Opin. Neurobiol. 14 (2004) 384-389
84. 123I]-β-CIT. Mov. Disord. 14 (1999) 436-442
85. Ishikawa A., Piao Y.S., Miyashita A., Kuwano R., Onodera O., Ohtake H., Suzuki M., Nishizawa M., and Takahashi H. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann. Neurol. 57 (2005) 429-434
86. Ives N.J., Stowe R.L., Marro J., Counsell C., Macleod A., Clarke C.E., Gray R., and Wheatley K. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329 (2004) 593
87. Jankovic J., and Kapadia A.S. Functional decline in Parkinson disease. Arch. Neurol. 58 (2001) 1611-1615
88. Jankovic J., and Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat. Disord. 8 (2002) 271-276
89. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestation. Mov. Disord. 20 Suppl. 11 (2005) S11-S16
90. Kahns S., Lykkebo S., Jakobsen L.D., Nielsen M.S., and Jensen P.H. Caspase-mediated parkin cleavage in apoptotic cell death. J. Biol. Chem. 277 (2002) 15303-15308
91. Kashani A., Lepicard E., Poirel O., Videau C., David J.P., Fallet-Bianco C., Simon A., Delacourte A., Giros B., Epelbaum J., Betancur C., and El Mestikawy S. Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. Neurobiol. Aging 28 (2007) 568-578
92. Kato H., Araki T., Imai Y., Takahashi A., and Itoyama Y. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease. J. Neurol. Sci. 208 (2003) 9-15
93. Kawamata H., McLean P.J., Sharma N., and Hyman B.T. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease associated Mutations. J. Neurochem. 77 (2001) 929-934
94. Kieburtz K. Designing neuroprotection trials in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S100-S109
95. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., and Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22 (2002) 2780-27891
96. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., and Rowan M.J. Amyloid ( protein immunotherapy neutralizes A( oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11 (2005) 556-561
97. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11 (2000) 211-213
98. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
99. Kruger R., Müller T., and Riess O. Involvement of alpha-synuclein in Parkinson's disease and other neurodegerative disorders. J. Neural Transm. 107 (2000) 31-40
100. Kukar T., Murphy M.P., Eriksen J.L., Sagi S.A., Weggen S., Smith T.E., Ladd T., Khan M.A., Kache R., Beard J., Dodson M., Merit S., Ozols V.V., Anastasiadis P.Z., Das P., Fauq A., Koo E.H., and Golde T.E. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A(42 production. Nat. Med. 11 (2005) 545-550
101. Kuopio A., Martilla R., Helenius H., Toivonen M., and Rinne U. The quality of life in Parkinson's disease. Mov. Disord. 15 (2000) 216-223
102. Landsbury Jr. P.T., and Brice A. Genetics of Parkinson'disease and biochemical studies of implicated gene products. Curr. Opin. Cell. Biol. 14 (2002) 653-660
103. Lang A.E., and Lozano A.M. Parkinson's disease: first of two parts. N. Engl. J. Med. 339 (1998) 1044-1053
104. Lang A.E., and Obeso J.A. Challenges in Parkinson's disease: restorations of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3 (2004) 309-316
105. Lansbury P.T. Back to the future: the "old-fashioned" way to new medications for neurodegeneration. Nat. Med. 10 Suppl. (2004) S51-S57
106. Larsen J.P., Boas J., and Erdal J.E. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur. J. Neurol. 6 (1999) 539-547
107. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., and Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53-Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8968-8973
108. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by β-Arrestins. Science 308 (2005) 512-517
109. LePen C., Wait S., Moutard-Martin F., Dujardin M., and Ziégler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 16 (1999) 59-69
110. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
111. Levi M.S., and Brimble M.A. A review of neuroprotective agents. Curr. Med. Chem. 18 (2004) 2383-2397
112. LeWitt P. Clinical trials of neuroprotection for Parkinson's disease. Neurology 63 Suppl. 2 (2004) S23-S31
113. Li W., and Lee M.K. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity. J. Neurochem. 93 (2005) 1542-1550
114. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury Jr. P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002) 209-218
115. Liu C.W., Giasson B.I., Lewis K.A., Lee V.M., Demartino G.N., and Thomas P.J. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280 (2005) 22670-22678
116. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., and Aebischer P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10813-10818
117. Lombardino A.J., Li X.C., Hertel M., and Nottebohm F. Replaceable neurons and neurodegenerative disease share depressed UCHL levels. PNAS 102 (2005) 8036-8041
118. Loopuijt L.D., and Schmidt W.J. The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Amino Acids 14 (1998) 17-23
119. Loschmann P.A., De Groote C., Smith L., Wullner U., Fischer G., Kemp J.A., Jenner P., and Klockgether T. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. Neurol. 187 (2004) 86-93
120. Lucassen P.J., Fuchs E., and Czéh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol. Psychiatry 55 (2004) 789-796
121. Lukaszevicz A.C., Sampaio N., Guegan C., Benchoua A., Couriaud C., Chevalier E., Sola B., Lacombe P., and Onteniente B. High sensitivity of protoplasmic cortical astroglia to focal ischemia. J. Cereb. Blood Flow Metab. 22 (2002) 289-298
122. Macleod A.D., Counsell C.E., Ives N., and Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst. Rev. 20 (2005) (CD004898)
123. Maingay M., Romero-Ramos M., and Kirik D. Viral vector mediated overexpression of human synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. CNS Spectrums 10 (2005) 235-244
124. Mandal P.K., Pettegrew J.W., Masliah E., Hamilton R.L., and Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem. Res. 31 (2006) 1153-1162
125. Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., and Youdim M.B.H. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17 (2003) 729-762
126. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., and Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53 (1999) 1858-1860
127. Marino M.J., Valenti O., and Conn P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging 20 (2003) 377-397
128. Marttila R.J., and Rinne U.K. Epidemiology of Parkinson's disease-an overview. J. Neural. Transm. 51 (1981) 135-148
129. Maruyama W., and Naoi M. Cell death in Parkinson's disease. J. Neurol. 249 Suppl. 2 (2002) 6-10
130. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implication for neurodegerative disorders. Science 287 (2000) 1265-1269
131. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., and Gallo K.A. LRRK2 on Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29 (2006) 286-293
132. McGeer P.L., and McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease Parkinsonism. Relat. Disord. 10 (2004) S3-S7
133. McNaught K.S., and Olanow C.W. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S73-S84
134. Mc Naught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (2004) 149-162
135. McNaught K.S., and Olanow C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60 (2006) 243-247
136. Meissner W., Hill M.P., Tison F., Gross C.E., and Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol. Sci. 25 (2004) 249-253
137. Mihm M.J., Schanbacher B.L., Wallace B.L., Wallace L.J., Uretsky N.J., and Bauer J.A. Free 3-nitrotyrosine causes striatal neurodegeneration in vivo. J. Neurosci. 21 (2001) RC149
138. Miller D.H. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 1 (2004) 284-294
139. Mitsumoto A., Nakagawa Y., Takeuchi A., Okawa K., Iwamatsu A., and Takanezawa Y. Oxidized forms of peroxiedoxins and DJ-1 on two dimensional gels increased in response to sublethal levels of paraquat. Free Radic. Res. 35 (2001) 301-310
140. Mizuno Y., Yoshino H., Ikebe S., Hattori N., Kobayashi T., Shimoda-Matsubayashi S., Matsumine H., and Kondo T. Mitochondrial dysfunction in Parkinson's disease. Ann. Neurol. 44 (1998) S99-S109
141. Mizuno Y., Hattori N., Yoshino H., Hatano Y., Satoh K., Tomiyama H., and Li Y. Progress in familial Parkinson's disease. J. Neural Transm. Suppl. 70 (2006) 191-204
142. 18F-dopa PET. J. Neurol. Neurosurg. Psychiatry 64 (1998) 314-319
143. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., and Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43 (1998) 561-575
144. Myllyla V.V., Sotaniemi K.A., Hakulinen P., Maki-Ikola O., and Heinonen E.H. Selegiline as the primary treatment of Parkinson's disease-a long-term double-blind study. Acta Neurol. Scand. 95 (1997) 211-218
145. Nair V.D., McNaught K.S., González-Maeso J., Sealfon S.C., and Olanow C.W. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281 (2006) 39550-39560
146. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., and Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165 (2000) 136-142
147. NET-PD Investigators. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann. Neurol. 57 (2005) 197-203
148. Nichols W.C., et al. Genetic screening for a single common LRRK2 mutation in familial. Parkinson's Disease. Lancet 365 (2005) 410-412
149. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006) 664-671
150. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68 (2007) 20-28
151. Obviagele B., Kidwell C.S., Starkman S., and Saver J.L. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr. Treat. Opt. Neurol. 5 (2003) 367-375
152. Olanow C.W. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can. J. Neurosci. 19 (1992) 108-112
153. Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J., Bushenbark K., Lilienfeld D., and Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 38 (1995) 771-777
154. Olanow C.W., Schapira A., and Agid Y. Causes of cell death and prospects for neuroprotection in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2002) 1-17
155. Olanow C.W., and Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov. Disord. 20 Suppl. 11 (2005) S3-S10
156. Orr H.T. Neuron protection agency. Nature 431 (2004) 747-748
157. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
158. Palhagen S., Heinonen E.H., Hagglund J., Kaugesaar T., Kontants H., Maki-Ikola O., Palm R., and Turunen J. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 51 (1998) 520-525
159. Palhagen S., et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (2006) 1200-1206
160. Pankratz N., and Foroud T. Genetic of Parkinson disease. NeuroRx 1 (2004) 235-242
161. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321 (1989) 1364-1371
162. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328 (1993) 176-183
163. Parkinson's Study Group. Design of a clinical trial comparing pramipexole to levodopa in early PD (CALM-PD). Clin. Neuropharmacol. 23 (2000) 34-44
164. Parkinson's Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
165. Parkinson's Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004) 2498-2508
166. Parkinson's Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61 (2004) 561-566
167. Petit P.X., Susin S.A., Zamzami N., Mignotte B., and Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett. 396 (1996) 7-13
168. Pirtosek Z., and Flisar D. Neuroprotection and dopamine agonists. Adv. Exp. Med. Biol. 541 (2004) 55-74
169. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
170. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., and Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67 (1995) 631-647
171. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
172. Przuntek H., Conrad B., Dichgans J., Kraus P.H., Krauseneck P., Pergande G., Rinne U., Schimrigk K., Schnitker J., and Vogel H.P. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur. J. Neurol. 6 (1999) 141-150
173. Ramsey C.P., and Giasson B.I. Role of mitochondrial dysfunction on Parkinson's disease: implication for treatment. Drugs Aging 24 (2007) 95-105
174. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who where treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342 (2000) 1484-1491
175. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., and Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003) 1234-1240
176. 2A receptors in the hippocampus and striatum of the rat. Neuroscience 132 (2005) 893-903
177. Robertson D.C., Schmidt O., Ninkina N., Jones P.A., Sharkey J., and Buchman V.L. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J. Neurochem. 89 (2004) 1126-1136
178. Rodriguez M., Barroso-Chinea P., Abdala P., Obeso J., and Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. Exp. Neurol. 169 (2001) 1163-1181
179. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., and Fisher P.B. Beta-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 (2005) 73-77
180. Sanchez-Gonzalez M.A., Garcia-Cabezas M.A., Rico B., and Cavada C. The primate thalamus is a key target for brain dopamine. J. Neurosci. 25 (2005) 6076-6083
181. Saporito M.S., Brown E.M., Miller M.S., and Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288 (1999) 421-427
182. Satoh J., and Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 189 (2001) 113-117
183. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., Nakanishi M., Nakamizo T., Yamakawa K., Shibasaki H., Yamamoto N., Akaike A., Inden M., Kitamura Y., Taniguchi T., and Shimohama S. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 279 (2004) 10710-10719
184. Schapira A.H.V. Disease modification in Parkinson's disease. Lancet Neurol. 3 (2004) 362-368
185. Schapira A., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
186. Schrag A., Jahanshali M., and Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov. Disord. 15 (2000) 1112-1118
187. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
188. Scriabine A. 1998 annual meeting of the society for Neuroscience: new drugs affecting the central nervous system. CNS Drug Rev. 4 (1998) 386-397
189. Sellal F., Nieoullon A., Michel G., Michel B.F., Lacomblez L., Geerts H., Delini Stula A., Bordet R., Bentue-Ferrer D., and Allain H. Pharmacology of Alzheimer's disease: appraisal and prospects. Dement. Geriatr. Cogn. Disord. 19 (2005) 229-245
190. Seppi K., Peralta C., Diem-Zangerl A., Puschban Z., Mueller J., Poewe W., and Wenning G.K. Placebo-controlled trial of riluzole in multiple system atrophy. Eur. J. Neurol. 13 (2006) 1146-1148
191. Sherer T.B., Richardson J.R., Testa C.M., Seo B.B., Panov A.V., Yagi T., Matsuno-Yagi A., Miller G.W., and Greenamyre J.T. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 100 (2007) 1469-1479
192. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 (2000) 302-305
193. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., and Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
194. Shoulson I. Where do we stand on neuroprotection? Where do we go from here?. Mov Disord. 13 Suppl. 1 (1998) 46-48
195. Singleton A.B. Altered α-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends Neurocsi. 28 (2005) 416-421
196. Singh N., Pillay V., and Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81 (2007) 14-29
197. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102 (2005) 216-222
198. Spedding M., Jay T., Costa e Silva J., and Perret L. A pathophysiological paradigm for the therapy of psychiatric disease. Nat. Rev./Drug Discov. 4 (2005) 467-476
199. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
200. 123I] β-CIT SPECT. J. Neural Transm. 107 (2000) 543-552
201. Stocchi F., Bonamartini A., Vacca L., and Ruggieri S. Motor fluctuations in levodopa treatment: clinical pharmacology. Eur. Neurol. 36 Suppl. 1 (1996) 38-42
202. Stocchi F., and Olanow C.W. Neuroprotection in Parkinson's disease: clinical trials. Ann. Neurol. 53 Suppl. 3 (2003) S87-S99
203. Storch A., Ludolph A.C., and Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural. Transm. 111 (2004) 1267-1286
204. Smith M.P., and Cass W.A. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 144 (2007) 1057-1066
205. Tabner B.J., Turnbull S., El-Agnaf O.M., and Allsop D. Formation of hydrogen peroxide and hydroxy radicals from Abeta and alpha-synuclein as posible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic. Biol. Med. 32 (2002) 1076-1083
206. Takuma K., Baba A., and Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog. Neurobiol 72 (2004) 111-127
207. Teismann P., and Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res. 318 (2004) 149-161
208. Tetrud J.W., and Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245 (1989) 519-522
209. Thobois S., Broussolle E., and Remy P. Advantages in limitations in the assessment of neuroprotective treatment of Parkinson's disease by functional imaging. Rev. Neurol. (Paris) 161 (2005) 385-393
210. Thompson L., Barraud P., Andersson E., Kirik D., and Bjorklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 25 (2005) 6467-6477
211. Tolosa E., and Wenning G. Poewe The diagnosis of Parkinson's disease. Lancet Neurol. 5 (2006) 75-86
212. Ton T.G., Heckbert S.R., Longstreth Jr. W.T., Rossing M.A., Kukull W.A., Franklin G.M., Swanson P.D., Smith-Weller T., and Checkoway H. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov. Disord. 21 (2006) 964-969
213. Turmel H., Hartmann A., Parain K., Douhou A., Srinivasan A., Agid Y., and Hirsch E.C. Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Mov. Disord. 16 (2001) 185-189
214. Turski L., Bressler K., Rettig K.J., Loschmann P.A., and Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349 (1991) 414-418
215. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., and Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11 (2005) 551-555
216. Twelves D., Perkins K.S., and Counsell C. Systematic review of incidence of Parkinson's disease. Mov. Disord. 18 (2003) 19-31
217. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., and Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11282-11286
218. Unger E.L., Eve D.J., Perez X.A., Reichenbach D.K., Xu Y., Lee M.K., and Andrews A.M. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol. Dis. 21 (2006) 431-443
219. Vajda F.J. Neuroprotection and neurodegenerative disease. J. Clin. Neurosci. 9 (2002) 4-8
220. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., and Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157 (2003) 1015-1022
221. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., and Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20 (2000) 6021-6029
222. Verney C., zecevic N., and Ezan P. Expression of calbindin D28K in the dopaminergic mesotelencephalic system in embryonic and fetal human brain. J. Comp. Neurol. 429 (2001) 45-58
223. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., Tieu K., and Przedborski S. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14 (2001) 483-489
224. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., and Lansbury Jr. P.T. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
225. von Campenhausen S., Bornschein B., Wick R., Botzel K., Sampaio C., Poewe W., Oertel W., Siebert U., Berger K., and Dodel R. Prevalence and incidence of Parkinson's disease in Europe. Eur. Neuropsychopharmacol. 15 (2005) 473-490
226. Watts R.L. The role of dopamine agonists in early Parkinson's disease. Neurology 49 (1997) S34-S38
227. Weiner W.J. The initial treatment of Parkinson's disease should begin with levodopa. Mov. Disord. 14 (1999) 716-724
228. Wersinger C., Prou D., Vernier P., and Sidhu A. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17 (2003) 2151-2153
229. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 (1997) 963-976
230. Whone A.L., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54 (2003) 93-101
231. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med. 8 (2002) 600-606
232. Yavich L., Oksman M., Tanila H., Kerokoski P., Hiltunen M., van Groen T., Puolivali J., Männistö P.T., Garcia-Horsman A., MacDonald E., Beyreuther K., Hartmann T., and Jäkälä P. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 20 (2005) 303-313
233. Youdim M.B.H., and Buccafusco J.J. Multifunctional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26 (2005) 27-35
234. Youdim M.B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., and Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79 (2005) 172-179
235. Yuan J., and Yankner B.A. Apoptosis in the nervous system. Nature 407 (2000) 802-809
236. Zecca L., Zucca F.A., Wilms H., and Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 26 (2003) 578-580
237. Zhang Z.X., and Roman G.C. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12 (1993) 195-208
238. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607